Esperion discloses DSE dispute over $300M milestone payments on CLEAR Outcomes data

Esperion Therapeutics, Inc.

NEXLETOL reduced MACE-4 by 13%, MACE-3 by 15%, heart attack by 23%, coronary revascularization by 19% vs placebo.
Company expects to submit FDA/EMA filings in H1 2023 for label inclusion of CV risk reduction.
Entitled to $200M-$300M milestone from DSE if EU label includes specific risk reduction; DSE disputes eligibility.
DSE argues primary endpoint MACE-4 reduction was 12.98%, below 20% threshold; company cites 23% MI reduction.
Company intends to enforce contractual rights; delay in payment could impact capital needs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.